Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsatile Lapatinib in Recurrent High-Grade Glioma
NCT02101905Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2016
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lapatinib in glioma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Lapatinib Ditosylate Intratumoral Concentration and Ratio of Phosphorylated (p)EGFR/Total EGFR in Tumor Tissue. Started Nov 2016; status: completed.
02
Drugs
lapatinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02101905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101905.